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Abstract: The isatin derivatives, Schiff bases, were synthesized by the reaction 
of isatin and various substituted primary amines and characterized by several 
spectroscopic methods. Investigation of the antimicrobial activity of the syn-
thesized compounds was performed by the agar dilution method, against dif-
ferent strains of bacteria and one fungus. The antioxidative activity of the syn-
thesized compounds was also determined. Some of the compounds showed sig-
nificant activity against the selected strains of microorganisms and antioxida-
tive activity.  
Keywords: isatin derivatives; Schiff bases; antimicrobial activity; antioxidative 
activity.  
INTRODUCTION 
The derivatives of isatin (indole-2,3-dione), as well as its Schiff and Man-
nich bases, have already been reported to show a variety of biological activities, 
such as antibacterial,1 antifungal2 and anti-HIV3,4 activities. The wide spectrum 
of isatin derivatives and their various chemical properties has led to their inc-
reasingly expanded use as precursors for the preparation of many biologically 
active compounds.5–11 Hydrazine derivatives of isatin were found to be active 
against Walker carcinosarcoma 256.10,12 Similarly, acetone- and ketone-deriva-
tives of isatin exhibited anticonvulsant activity.13 Another class of thiosemicar-
bazone derivates of isatin was found to exhibit interesting applications as research 
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tools in physiological studies.14–18 Similarly, many other isatin-derived com-
pounds possess a wide spectrum of medicinal properties and have thus been stu-
died for activity against tuberculosis,19,20 leprosy,21 fungal,22–26 viral26 and bac-
terial18,27 infections, trypanosomiasis28 and as anticonvulsants.29–31 Therefore 
the antimicrobial activity determination of this class of compounds is of signi-
ficance and it has already been performed by the diameter of zone of inhibition 
method.32,33 
Besides antimicrobial activity, the antioxidative capacities of a compound 
have become more and more significant nowadays. Oxidation reactions can pro-
duce free radicals, which, in turn, can initiate chain reactions. Antioxidants ter-
minate these chain reactions by being oxidized themselves, thereby removing 
free radical intermediates and inhibiting other oxidation reactions. Such are 
thiols, ascorbic acid and polyphenols that are also reducing agents.34 Antioxi-
dants are widely used in dietary supplements and have been investigated for the 
prevention of diseases such as cancer, or coronary heart disease.34 Antioxidants 
also have many industrial uses, i.e., as preservatives in food and cosmetics and 
even to prevent the degradation of rubber and gasoline.35  
Taking all this into consideration, it is deemed of interest to test the anti-
microbial and antioxidative activity of synthesized isatin derivatives, in order to 
estimate their activity potential.  
In this study, a series of six isatin derivatives, two of them new, which could 
be classified as Schiff bases, was synthesized, characterized and tested for their 
antimicrobial and antioxidative activity.  
EXPERIMENTAL 
Chemistry 
The examined Schiff bases were synthesized by the reaction of isatin and the required 
primary amine, Scheme 1. All employed chemicals were of p.a. quality (Fluka–Alrich). The 
list of synthesized compounds is given in Table I. 
 
Scheme 1. The synthesis of the isatin derivatives. 
Synthesis. Isatin (5 mmol) was dissolved in methanol (40 mL), and corresponding reac-
tants (amine (R–NH2, 5 mmol) and glacial acetic acid (1 mL) in the given order) were added. 
Reaction mixture was refluxed at 70 °C for 6 h under stirring at atmospheric pressure. 
ubsequently, the mixture was left overnight without stirring at room temperature. The 
obtained crystals were filtered off, dried and recrystallized from methanol. On average, the 
yield was about 70–79 % (details are given in the Supplementary material). 
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TABLE I. The synthesized isatin derivatives 
Compound R Compound name 
1 
N
N
S
SH
 
1,3-dihydro-3-[(5-mercapto-1,3,4-thiadiazol-2-yl)imino]-2H- 
-indol-2-one 
2 
N
S
 
1,3-dihydro-3-(2-benzothiazolylimino)-2H-indol-2-one 
3 
CN
1,3-dihydro-3-[(4-cyanophenyl)imino]-2H-indol-2-one 
4 
N
S
NO2
 
1,3-dihydro-3-[(5-nitro-2-thiazolyl)imino]-2H-indol-2-one 
5 
N
CH3
 
1,3-dihydro-3-[(5-methyl-2-pyridyl)imino]-2H-indol-2-one 
6 
NO2
 
1,3-dihydro-3-[(4-nitrophenyl)imino]-2H-indol-2-one 
Characterization  
Melting points were determined on a Stuart SMP 30 melting point apparatus. The FTIR 
spectra were recorded on Bomem MB100 spectrometer, using the standard KBr pellet 
technique. The 1H-NMR and 13C-NMR spectral measurements were performed on a Bruker 
AC 250 spectrometer at 250 MHz for the 1H-NMR and 62.89 MHz for the 13C-NMR spectra. 
The spectra were recorded at room temperature in DMSO-d6. Elemental analysis was realized 
using an Elemental Vario EL III micro-analyzer.  
In vitro antimicrobial activity 
The antimicrobial activity of all synthesized compounds 1–6 was determined on a wide 
range of different microorganisms by the broth micro-dilution method.36 The advantage of 
this method, in comparison to the technique of the diameter of inhibition zones,32,33 lies in its 
capability to quantitatively determine antimicrobial activity and give a more precise insight 
into the effect of every examined compound on the applied bacterial strains.  
The broth micro-dilution method36 was applied to determine the minimal inhibitory 
concentrations (MIC) of the investigated compounds against nine American Type Cell Col-
lection (ATCC) bacterial strains and one strain of yeast, Candida albicans (Table II). The 
method was performed in agreement with Clinical and Laboratory Standard Institute (CLSI 
2005). 
The active microbial cultures were prepared from lyophilized standard strains by trans-
ferring them to test tubes with the appropriate broth. The nutrient broth was used for bacterial 
strains, except for L. monocytogenes, for which the soya triptose broth was used. The malt 
broth was used for C. albicans. The density of microbial suspensions was set approximately at 
105 CFU (Colony Forming Units), using the appropriate broth. 
All examined compounds were first dissolved in 5 % dimethyl sulphoxide to a concen-
tration of 2.5 mg mL-1, and then series of concentrations were prepared by two-fold dilution, 
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using the appropriate broth. The serial concentrations were prepared directly in micro-titre 
plates and the final volume of specimens was 50 µL. The investigated concentrations were in 
the range from 0.0024 to 1.25 mg mL-1. In the last column only the appropriate broth was 
added. Then 50 µL of each microbial suspension were added in each well, so that the final 
concentrations of the examined extracts were half of those at the beginning, and the final 
volume was 100 µL in each well. Triphenyltetrazolium chloride (TTC), in concentration of 
0.75 vol. % was used as the growth indicator. If growth of a microbial strain occurs, this 
indicator gives a rosy–red colour to the broth. The plates with bacteria were incubated at 37 
°C and that with candida at 32 °C, for 24 h. The results were read the following day and the 
MIC value of each compound on every strain was taken as the concentration at which there 
was no development of a red colour. All tests were performed in triplicate and the MIC values 
were constant. 
TABLE II. The examined bacteria and fungus types 
No. Microorganism ATCC No. 
1 Staphylococcus aureus 6538 
2 Lysteria monocytogenes 19115 
3 Enterococcus faecalis 29212 
4 Shigella sonnei 29930 
5 Salmonella enteritidis 13076 
6 Yersinia enterocolitica 27729 
7 Escherichia coli 35150 
8 Proteus hauseri 13315 
9 Pseudomonas aeruginosa 27853 
10 Candida albicans 10259 
Antioxidative activity 
All the synthesized compounds were screened for their antioxidative activity by the 
2,2-diphenylpicrylhydrazyl (DPPH) assay.37  
DPPH method. A methanolic DPPH solution (0.037 mg mL-1) was prepared and kept in 
the dark before analysis. Methanolic solutions of the compounds were prepared in various 
concentrations, depending on the examined compound. 200 μL of each sample was added to 
2.8 mL of DPPH solution and reaction mixture was kept in the dark for 20 min. A blind test 
was performed by adding 200 μL of methanol in 2.8 mL of DPPH solution and the absorbance 
of both the blind check and the investigated samples was measured at 517 nm. The percent of 
DPPH reduction, DPPHred, was calculated from the equation: 
 ( )BT SXred
BT
100
A A
DPPH
A
−
=  
where ABT is the absorbance in the blind test, and ASX corresponds to absorbance of a specific 
sample.  
RESULTS AND DISCUSSION 
Characterization of the synthesized compounds 
The structures of all synthesized compounds 1–6 from Table I were confir-
med by melting points, FTIR, 1H-,13C-NMR spectra and also by elemental anal-
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ysis for compounds 1 and 5. The data for compound characterization are given in 
the Supplementary material to this paper. 
To the best of our knowledge, there are no literature data that compounds 1 
and 5 had been hitherto synthesized, therefore they could be classified as new 
compounds. Compound 2 has already been used for the synthesis of metal com-
plexes,32 commercial sources exist for compound 3*, and the antimicrobial acti-
vities of compounds 438 and 633 have also already been researched. However, no 
available FTIR or NMR spectra of them could be found in the mentioned studies. 
Antimicrobial screening 
All the examined compounds showed considerable activity against all the 
tested strains of microorganism except for compound 3, which exhibited rather 
weak activity against E. coli, P. aeruginosa and C. albicans in the range of the 
investigated concentrations. The overall activity could be described as moderate 
with some selectivity against Gram-positive (G+) or Gram-negative (G–) strains 
of bacteria, or the yeast C. albicans.  
The selectivity to G– bacteria, which is an important property for the phar-
macological activity, also appeared in a few cases. This property enables the 
antibiotic agent based on a G– selective compound to be taken without the sup-
port of an agent that recovers the gastrointestinal tract, as the natural bacteria it 
contains are G+. The activity of certain examined isatin derivatives against the 
fungus was also important because they could be applied as antifungal agents.  
The overall results of the antimicrobial screening are given in Table III. 
TABLE III. Antimicrobial activity of the examined compounds (MIC / mM) 
Cmpd. 
Microorganism 
S. au-
reus 
L. mono-
cytogenes 
E. fae-
calis 
S. son-
nei 
S. ente-
ritidis 
Y. entero-
colytica 
E. 
coli 
P. hau-
seri 
P. aeru-
ginosa 
C. albi-
cans 
1 0.16 0.32 2.56 1.28 2.56 0.64 2.56 0.64 5.12 2.56 
2 2.24 1.12 2.24 1.12 1.12 1.12 1.12 1.12 2.24 2.24 
3 2.53 0.63 2.53 5.06 >5.06 2.53 >5.06 5.06 >5.06 >5.06 
4 0.57 2.28 0.57 0.57 1.14 1.14 1.14 1.14 2.28 2.28 
5 5.27 2.64 2.64 0.66 5.27 0.33 2.64 0.99 2.64 2.64 
6 4.68 1.17 4.68 0.59 4.68 0.59 4.68 1.17 2.34 1.17 
Some of the isatin derivatives synthesized in this research displayed signi-
ficant activity against the various examined bacteria and fungus, while some 
others were only moderately or even weakly active. 
Compound 1 exhibited the most prominent overall activity on both G+ (S. 
aureus and L. monocytogenes) and G– (Y. enterocolitica and P. hauseri) bacterial 
strains. The highest activity of this compound was registered against S. aureus 
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(MIC value of 0.16 mM), followed closely by L. monocytogenes (MIC value of 
0.32 mM). 
However, compound 1 displayed only moderate activity on Y. enterocolitica, 
unlike compound 5, which had a rather significant activity against this specific 
strain (MIC value of 0.33 mM). Except for this example, the overall antimic-
robial activity of compound 5 was not as strong as that of compound 1. Besides 
against Y. enterocolitica, it showed moderate activity on S. sonei and somewhat 
slighter on P. hauseri. 
Compound 6 behaved somewhat similar to compound 5 but without any 
really prominent antimicrobial activity. It displayed only moderate activity 
against Y. enterocolitica and S. sonei.  
Compounds 2 and 3 generally showed comparably weak antimicrobial 
activity. The only observation that could be of interest was the relative selectivity 
of compound 3 to L. monocytogenes. (MIC value of 0.63 mM) 
Compound 4 exhibited certain moderate activity against S. aureus, E. fae-
calis and S. sonei.  
Antioxidative activity 
The results of DPPH analysis showed that compound 1 displayed the most 
expressed antioxidative activity, while the other investigated compounds, inc-
luding pure isatin, showed very slight, if any, activity. 
With increasing concentration of compound 1, the absorbance of DPPH 
decreased, displaying a linear dependence of % DPPHred in the range of 
examined concentrations (c, mM), which is described by the following equation: 
 DPPHred [%] = 5.099 + (101.02±5.24)c 
 R = 0.995, s = 3.17, n = 6 
DPPHred is actually the percent of DPPH reduction and c is the concentra-
tion of compound 1, given in mM. The equation enables the precise deter-
mination of the concentration which reduces 50 % of the DPPH concentration 
(DC50).  
Compound 1 showed prominent antioxidative activity, with a DC50 value of 
0.444 mM. Ascorbic acid was used as a standard, with a DC50 value of 0.341 
mM (see Fig. S-1 of the Supplementary material), which is quite comparable.  
CONCLUSIONS 
Six isatin derivatives were synthesized, of which two were new, in order to 
test their antimicrobial activity. Their structure was confirmed by melting points, 
and FTIR and NMR spectra. Antimicrobial screening was performed on nine 
bacterial strains and one yeast strain, by the broth micro-dilution method. Some 
compounds showed relative selectivity to certain bacterial strains. In several 
cases, slight selectivity could be noticed against certain bacterial strains. Com-
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pounds 1, 5 and 6 exhibited relative selectivity against the G– bacteria S. sonei, 
Y. enterocolitica and P. hauseri, shown by the MIC values being approximately 4 
to 16 times lower than for other examined G– bacteria, which means that the 
effects of the mentioned compounds were considerably stronger on these three 
bacterial strains, than on the others tested. Compounds 3 and 6 showed relative 
selectivity to L. monocytogenes – if only the other G+ bacteria were taken into 
consideration, with approximately 4 times better activity on L. monocytogenes 
than on the other examined G+ bacteria. Compound 1 showed significant activity 
against both S. aureus and L. monocytogenes. 
Overall effect of the examined compounds on selected bacterial and yeast 
strains could be described as moderate, with the exception of compounds 1 and 5 
which exhibited prominent activity to S. aureus and L. monocytogenes (1) and Y. 
enterocolitica (5) and would be of interest for further analysis. Compounds 5 and 
6 showed somewhat better activity to certain G– strains than to G+ strains, which 
makes them interesting from the medicinal point of view.  
The DPPH reduction test was performed to investigate the antioxidative acti-
vity of the synthesized compounds and compound 1 displayed significant acti-
vity, which makes it of highest interest for further study. 
SUPPLEMENTARY MATERIAL 
Characterization data of the synthesized compounds and graph for antioxidative activity 
of compound 1 are available electronically from http://www.shd.org.rs/JSCS/, or from the 
corresponding author on request. 
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И З В О Д  
СИНТЕЗА, АНТИМИКРОБНА И АНТИОКСИДАТИВНА АКТИВНОСТ 
ДЕРИВАТА ИЗАТИНА  
ГАВРИЛО М. ШЕКУЛАРАЦ1, ЈАСМИНА Б. НИКОЛИЋ2, ПРЕДРАГ ПЕТРОВИЋ3, БРАНКО БУГАРСКИ3, 
БОБАН ЂУРОВИЋ4 и САША Ж. ДРМАНИЋ2 
1Институт за хемију, технологију и металургију, Универзитет у Београду, Његошева 12, Београд, 
2Катедра за органску хемију, Технолошко–металуршки факултет, Универзитет у Београду, 
Карнегијева 4, 11120 Београд, 3Катедра за хемијско инжењерство, Технолошко–металуршки 
факултет, Универзитет у Београду, Карнегијева 4, 11120 Београд и 4Факултет техничких наука, 
Кнеза Милоша 7, 38220 Косовска Митровица 
Деривати изатина, Шифове базе, синтетисани су реакцијом између изатина и раз-
личитих супституисаних примарних амина, и затим окарактерисани са неколико спек-
троскопсих метода. Испитивање антимикробне активности синтетисаних једињења је 
изведено бујон-микродилуционом методом, на различитим сојевима бактерија и једној 
гљивици. Такође је испитана и антиоксидативна активност синтетисаних једињења. Нека 
од њих су показала значајну како антимикробну, тако и антиоксидативну активност.  
(Примљено 9. јула, ревидирано 17. августа, прихваћено 18. августа 2014) 
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